Martin Merschhemke

3.7k total citations · 1 hit paper
33 papers, 2.1k citations indexed

About

Martin Merschhemke is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Martin Merschhemke has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Martin Merschhemke's work include Multiple Sclerosis Research Studies (17 papers), Epilepsy research and treatment (6 papers) and Peripheral Neuropathies and Disorders (4 papers). Martin Merschhemke is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Epilepsy research and treatment (6 papers) and Peripheral Neuropathies and Disorders (4 papers). Martin Merschhemke collaborates with scholars based in United States, Germany and Switzerland. Martin Merschhemke's co-authors include Louis Lemieux, David R. Fish, Afraim Salek‐Haddadi, Karl Friston, John S. Duncan, Heinz‐Joachim Meencke, Bruce Cree, Norman Putzki, Benjamin Greenberg and Dieter A. Häring and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Neuroscience.

In The Last Decade

Martin Merschhemke

31 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

2016 335 citations Fred Lublin, David H. Miller et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Merschhemke United States	19	704	623	619	583	419	33	2.1k
Zuzanna Michalak Switzerland	23	792 1.1×	437 0.7×	401 0.6×	96 0.2×	604 1.4×	38	2.0k
Samson Antel Canada	18	306 0.4×	256 0.4×	525 0.8×	159 0.3×	185 0.4×	24	1.4k
Benedetta Bodini France	29	1.2k 1.8×	274 0.4×	145 0.2×	155 0.3×	447 1.1×	67	2.1k
Alessandro Meani Italy	24	994 1.4×	152 0.2×	257 0.4×	449 0.8×	491 1.2×	89	1.8k
Ahmed Toosy United Kingdom	33	1.9k 2.7×	173 0.3×	215 0.3×	458 0.8×	974 2.3×	88	3.5k
Arianna Sala Italy	24	660 0.9×	154 0.2×	336 0.5×	385 0.7×	395 0.9×	67	1.8k
Stefan D. Roosendaal Netherlands	22	1.4k 2.0×	140 0.2×	107 0.2×	378 0.6×	547 1.3×	45	2.4k
Maria Liguori Italy	29	1.4k 2.0×	357 0.6×	152 0.2×	139 0.2×	667 1.6×	70	2.7k
Carsten Lukas Germany	27	1.2k 1.7×	430 0.7×	131 0.2×	131 0.2×	746 1.8×	111	2.4k
Didier Scavarda France	29	138 0.2×	765 1.2×	1.2k 1.9×	903 1.5×	727 1.7×	112	2.8k

Countries citing papers authored by Martin Merschhemke

Since Specialization

Citations

This map shows the geographic impact of Martin Merschhemke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Merschhemke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Merschhemke more than expected).

Fields of papers citing papers by Martin Merschhemke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Merschhemke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Merschhemke. The network helps show where Martin Merschhemke may publish in the future.

Co-authorship network of co-authors of Martin Merschhemke

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Merschhemke. A scholar is included among the top collaborators of Martin Merschhemke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Merschhemke. Martin Merschhemke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riley, Nicholas, Michael Barnett, Simon Broadley, et al.. (2024). Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons. Therapeutic Advances in Neurological Disorders. 17. 4233520541–4233520541. 2 indexed citations

Ziemssen, Tjalf, Douglas L. Arnold, Enrique Álvarez, et al.. (2022). Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13. 852563–852563. 28 indexed citations

Bar‐Or, Amit, J. de Sèze, Jorge Correale, et al.. (2021). Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300). Neurology. 96(15_supplement). 9 indexed citations

Hauser, Stephen L., Amit Bar‐Or, Jeffrey A. Cohen, et al.. (2020). B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356). Neurology. 94(15_supplement). 5 indexed citations

Bar‐Or, Amit, Edward Fox, Alexandra Goodyear, et al.. (2020). Onset of B-cell Depletion and Suppression of MRI Activity with Ofatumumab Treatment in Relapsing Multiple Sclerosis: The APLIOS Study (3971). Neurology. 94(15_supplement). 1 indexed citations

Arnold, Douglas L., Brenda Banwell, Amit Bar‐Or, et al.. (2020). Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMSstudy. Journal of Neurology Neurosurgery & Psychiatry. 91(5). 483–492. 28 indexed citations

Kappos, Ludwig, Amit Bar‐Or, Jeffrey A. Cohen, et al.. (2019). Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096). Neurology. 92(15_supplement). 1 indexed citations

Kühle, Jens, Harald Kropshofer, Rolf Meinert, et al.. (2018). Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients (S24.004). Neurology. 90(15_supplement). 1 indexed citations

Chitnis, Tanuja, Douglas L. Arnold, Brenda Banwell, et al.. (2018). Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine. 379(11). 1017–1027. 199 indexed citations

10.

Wolinsky, Jerry S., Dieter A. Häring, Maria Pia Sormani, et al.. (2016). Brain Volume as a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial (S51.007). Neurology. 86(16_supplement). 1 indexed citations

11.

Lublin, Fred, David H. Miller, Mark S. Freedman, et al.. (2016). Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 387(10023). 1075–1084. 335 indexed citations breakdown →

12.

Chitnis, Tanuja, Brenda Banwell, Goeril Karlsson, et al.. (2014). Fingolimod In Pediatric MS: Design Of A Double-Blind Study Versus Interferon β-1a IM (P2.238). Neurology. 82(10_supplement).

13.

Schmitt, Friedhelm C., Christoph Dehnicke, Martin Merschhemke, & Heinz‐Joachim Meencke. (2010). Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy & Behavior. 17(4). 565–568. 30 indexed citations

14.

Blümcke, Ingmar, Iris Kistner, Hans Clusmann, et al.. (2009). Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies. Acta Neuropathologica. 117(5). 535–544. 108 indexed citations

15.

Salek‐Haddadi, Afraim, Beate Diehl, Khalid Hamandi, et al.. (2006). Hemodynamic correlates of epileptiform discharges: An EEG-fMRI study of 63 patients with focal epilepsy. Brain Research. 1088(1). 148–166. 216 indexed citations

16.

Gabriel, Siegrun, Marleisje Njunting, Joern K. Pomper, et al.. (2004). Stimulus and Potassium-Induced Epileptiform Activity in the Human Dentate Gyrus from Patients with and without Hippocampal Sclerosis. Journal of Neuroscience. 24(46). 10416–10430. 119 indexed citations

17.

Salek‐Haddadi, Afraim, Louis Lemieux, Martin Merschhemke, et al.. (2003). EEG quality during simultaneous functional MRI of interictal epileptiform discharges. Magnetic Resonance Imaging. 21(10). 1159–1166. 14 indexed citations

18.

Salek‐Haddadi, Afraim, Louis Lemieux, Martin Merschhemke, et al.. (2003). Functional magnetic resonance imaging of human absence seizures. Annals of Neurology. 53(5). 663–667. 205 indexed citations

19.

Mitchell, Tejal N., S. L. Free, Martin Merschhemke, et al.. (2003). Reliable callosal measurement: population normative data confirm sex-related differences.. American Journal of Neuroradiology. 24(3). 410–8. 54 indexed citations

20.

Salek‐Haddadi, Afraim, Martin Merschhemke, Louis Lemieux, & David R. Fish. (2002). Simultaneous EEG-Correlated Ictal fMRI. NeuroImage. 16(1). 32–40. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact